Xenikos presents promising new data from expanded access
Nijmegen the Netherlands December 9 2019The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in
Get Price
Results from an Expanded Access Program of Anti-CD3/CD7
Results from an Expanded Access Program of Anti-CD3/CD7 Immunotoxin Combination (T-Guard®) for the Treatment of Steroid-Refractory Acute Gvhd
Get Price
Experimental Pharmaceuticals for Steroid-Refractory Acute
Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. Abstract Acute GVHD (aGVHD) is a significant complication after allogeneic hematopoietic cell transplantation (HCT) occurring in up to 70 of HCT recipients. Steroid-refractory aGVHD represents a subset of patients failing initial therapy and is particularly
Get Price
FDA Sets Review Date for Remestemcel-L for Steroid
Jul 21 2020 · Kurtzberg J Prockop S Chaudhury S et al. Study 275 updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children.
Get Price
MaaT Pharma to Provide Clinical Data for Lead Microbiome
Mar 11 2021 · In addition to the early access program MaaT Pharma investigated its lead candidate MaaT013 in a multi-center single-arm open-label Phase 2
Get Price
MaaT Pharma Announces Positive Data for Its Lead
Aug 31 2020 · In the presented evaluation eleven patients with steroid-dependent (n=3) or steroid-refractory (n=8) intestinal aGVHD following allogeneic hematopoietic stem cell transplantation received at least one and up to three doses of MaaT013 as part of a compassionate program. Most patients (n=10) had developed GI-predominant aGVHD.
Get Price
Xenikos presents promising new data from expanded access
"More effective therapies for steroid-refractory acute graft-versus-host disease are urgently needed " said Dr. Van der Velden. "The results of the Phase 1/2 clinical trial and now in the expanded access program show highly promising response rates including complete remission and overall survival rates that are substantially
Get PriceMaaT Pharma to Provide Clinical Data for Lead Microbiome
Mar 11 2021 · In addition to the early access program MaaT Pharma investigated its lead candidate MaaT013 in a multi-center single-arm open-label Phase 2 clinical trial called HERACLES to evaluate the safety and efficacy of MaaT013 in gastrointestinal-predominant steroid-refractory acute GvHD (GI SR-aGvHD) patients (NCT).
Get Price
Xenikos Presents Promising New Data from Expanded Access
Dec 09 2019 · The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation.
Get Price
Xenikos Presents Promising New Data from Expanded Access
Dec 09 2019 · The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation.
Get Price
Expanded Access Program With MaaT013 in Steroid-refractory
Expanded Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (ATLAS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it
Get Price
MaaT Pharma to Provide Data Update for Lead Microbiome
Nov 26 2020 · MaaT Pharma announced today that updated results from its compassionate use program for lead microbiome therapeutic MaaT013 will be reported in an oral presentation at the virtual 62nd American Society of Hematology (ASH) Annual Meeting held from December 5 -8 2020. The results include data from 29 patients with gastrointestinal acute Graft-versus-Host-Disease (aGvHD)
Get Price
Successful and Safe Treatment of Intestinal Graft-Versus
Nov 05 2020 · Twenty-nine allo-HSCT recipients with steroid-dependent or SR intestinal GvHD (classical aGVHD n=22 late-onset aGVHD n=2 aGvHD with overlap syndrome n=5) were treated with MaaT013 biotherapeutic as part of a compassionate use/expanded access treatment program of the developer MaaT Pharma.
Get Price
FDA Sets Review Date for Remestemcel-L for Steroid
Jul 21 2020 · Kurtzberg J Prockop S Chaudhury S et al. Study 275 updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children.
Get Price
Xenikos presents promising new data from expanded access
Dec 09 2019 · Nijmegen the Netherlands December 9 2019The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem
Get Price
MaaT Pharma Presents Positive Updated Results with its
Dec 07 2020 · MaaT Pharma announced today positive updated clinical results from its lead full-ecosystem microbiome restoration biotherapeutic MaaT013 at the virtual 62nd American Society of Hematology (ASH
Get Price
Study 275 Updated Expanded Access Program for Remestemcel
May 01 2020 · Study 275 Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. Author links open overlay panel Joanne Kurtzberg 1 Susan Prockop 2 Sonali Chaudhury 3 Biljana Horn 4 Eneida Nemecek 5 Vinod Prasad 1 Prakash Satwani 6 Pierre Teira 7 Jack Hayes 8 Elizabeth Burke 8 for the MSB-275 Study
Get Price
MaaT Pharma Announces Positive Topline Results from Phase
Mar 17 2021 · The HERACLES trial data as well as the early access program results obtained in a larger and more diverse subpopulation of patients demonstrate the real-life benefit MaaT013
Get Price
MaaT Pharma Presents Positive Updated Results with its
MaaT Pharma announced today positive updated clinical results from its lead full-ecosystem microbiome restoration biotherapeutic MaaT013 at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. The data stems from a compassionate use/expanded access treatment program in France called Autorisation Temporaire d Utilisation Nominative (ATUn) using MaaT013 to treat patients
Get Price
(PDF) Study 275 Updated Expanded Access Program for
Study 275 Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) in Children February 2020 Biology of Blood and Marrow Transplantation
Get Price
MaaT Pharma to Provide Clinical Data for Lead Microbiome
Mar 11 2021 · In addition to the early access program MaaT Pharma investigated its lead candidate MaaT013 in a multi-center single-arm open-label Phase 2 clinical trial called HERACLES to evaluate the safety and efficacy of MaaT013 in steroid-refractory gastrointestinal-predominant acute GvHD (SR-GI-aGvHD) patients (NCT).
Get Price
Xenikos presents promising new data from expanded access
"More effective therapies for steroid-refractory acute graft-versus-host disease are urgently needed " said Dr. Van der Velden. "The results of the Phase 1/2 clinical trial and now in the expanded access program show highly promising response rates including complete remission and overall survival rates that are substantially
Get PriceXenikos Presents Promising New Data from Expanded Access
Dec 09 2019 · The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation.
Get Price
Study 275 Updated Expanded Access Program for Remestemcel
Study 275 Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.
Get PriceSuccessful and Safe Treatment of Intestinal Graft-Versus
Nov 05 2020 · Twenty-nine allo-HSCT recipients with steroid-dependent or SR intestinal GvHD (classical aGVHD n=22 late-onset aGVHD n=2 aGvHD with overlap syndrome n=5) were treated with MaaT013 biotherapeutic as part of a compassionate use/expanded access treatment program of the developer MaaT Pharma.
Get Price
MaaT Pharma Presents Positive Updated Results with its
MaaT Pharma announced today positive updated clinical results from its lead full-ecosystem microbiome restoration biotherapeutic MaaT013 at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. The data stems from a compassionate use/expanded access treatment program in France called Autorisation Temporaire d Utilisation Nominative (ATUn) using MaaT013 to treat patients
Get Price
MaaT Pharma to Provide Clinical Data for Lead Microbiome
MaaT Pharma announced today that data from its early access program for lead microbiome ecosystem therapeutic MaaT013 will be reported in an oral presentation at the virtual 47th Annual Meeting
Get Price
MaaT Pharma Announces Positive Topline Results from Phase
The HERACLES trial data as well as the early access program results obtained in a larger and more diverse subpopulation of patients demonstrate the real-life benefit MaaT013 can provide to these
Get Price
MaaT Pharma Presents Positive Updated Results with its
Dec 07 2020 · The data stems from a compassionate use/expanded access treatment program in France called Autorisation Temporaire d Utilisation Nominative (ATUn) using MaaT013 to treat patients that developed acute Graft-versus-Host-Disease with GI involvement (GI aGvHD) following allogeneic hematopoietic cell transplantation (allo-HCT) and were refractory to multiple lines of treatments
Get Price
Xenikos presents promising new data from expanded access
Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting • MC Services corporate website. 5295.
Get Price
